Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations have improved dramatically with EGFR and ALK ty...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Association of Physical Chemists (IAPC)
2016-10-01
|
| coleção: | ADMET and DMPK |
| Assuntos: | |
| Acesso em linha: | http://pub.iapchem.org/ojs/index.php/admet/article/view/337 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|